References
- Bernasconi A., Cendes F., Theodore W.H., Gill R.S., Koepp M. J., Hogan R.E. et al.: Recommendations for using structural magnetic resonance imaging in the care of patients with epilepsy: A consensus report from the International League Against Epilepsy Neuroimaging Task Force. Epilepsia, 2019, 60: 1054–1068. doi: 10.1111/epi.15612
- de Bruijn M.A.A.M., Bastiaansen A.E.M., Mojzisova H., van Sonderen A., Thijs R.D., Majoie M.J.M. et al.:Antibodies Contributing to Focal Epilepsy Signs and Symptoms Score. Ann Neurol, 2021, 89: 698–710. Doi: 10.1002/ana.26013
- Cabezudo-García P., Ciano-Petersen N.L., Mena-Vázquez N., Ortega-Pinazo J., Postigo-Pozo M.J., García-Martín G. et al.: Prevalence of Neural Autoantibodies in Paired Serum and Cerebrospinal Fluid in Adult Patients with -Resistant Temporal Lobe Epilepsy of Unknown Etiology. J. Clin. Med., 2021, 10: 4843. doi: 10.3390/jcm10214843
- Cabezudo-García P., Mena-Vázquez N., Ciano-Petersen N.L., García-Martín G., Estivill-Torrús G., Serrano-Castro PJ.: Prevalence of Neural Autoantibodies in Epilepsy of Unknown Etiology: Systematic Review and Meta-Analysis. Brain Sci., 2021, 11: 392. doi: 10.3390/brainsci11030392
- Cabezudo-García P., Mena-Vázquez N., Villagrán-García M., Serrano-Castro PJ.: Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review. Seizure, 2018, 59: 72–76. Doi: 10.1016/j.seizure.2018.05.004
- Dalic L., Cook M.J.: Managing drug-resistant epilepsy: challenges and solutions. Neuropsychiatr Dis Treat, 2016, 12: 2605– 2616. doi: 10.2147/NDT.S84852
- Dubey D., Pittock S.J., McKeon A.: Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability. Epilepsia, 2019, 60: 367–369. Doi: 10.1111/epi.14649
- Dubey D., Pittock S.J., Kelly C.R., McKeon A., Lopez-Chiriboga A.S., Lennon V.A. et al.: Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol, 2018, 83:166–177. Doi: 10.1002/ana.25131
- Dubey D., Singh J., Britton J.W., Pittock S.J., Flanagan E.P., Lennon V.A. et al.: Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia, 2017, 58: 1181–1189. Doi: 10.1111/epi.13797
- Ekizoglu E., Baykan B., Sezgin M., Erdag E., Gundogdu-Un-verengil G., Vanli-Yavuz E.N. et al.: Follow-up of patients with epilepsy harboring antiglycine receptor antibodies. Epilepsy Behav, 2019, 92: 103–107. doi: 10.1016/j.yebeh.2018.09.034
- Feyissa A.M., López Chiriboga A.S., Britton J.W.: Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm, 2017, 4: 353. doi: 10.1212/NXI.0000000000000353
- Graus F., Titulaer M.J., Balu R., Benseler S., Bien C.G., Celluc-ci T. et al.: A clinical approach to the diagnosis of autoimmune encephalitis. Lancet Neurol, 2016, 15:391–404. doi: 10.1016/S1474-4422(15)00401-9
- Hottenrott T., Dersch R., Berger B., Rauer S., Huzly D., Stich O.: The MRZ reaction in primary progressive multiple sclerosis. Fluids Barriers CNS, 2017, 14: 2. doi: 10.1186/s12987-016-0049-7
- Husari K.S., Dubeycorresponding D.: Autoimmune Epilepsy. Neurotherapeutics, 2019, 16: 685–702. doi: 10.1007/s13311-019-00750-3
- Jang Y., Kim D.W., Yang K.I., Byun J.I., Seo J.G., No Y. J. et al.: Drug Committee of Korean Epilepsy Society. Clinical Approach to Autoimmune Epilepsy. J. Clin. Neurol., 2020, 16: 519–529. Doi: 10.3988/jcn.2020.16.4.519
- Kelley B.P., Patel S.C., Marin H.L., Corrigan J.J., Mitsias P.D., Griffith B.: Autoimmune encephalitis: Pathophysiology and imaging review of an overlooked diagnosis. Am. J. Neuroradiol, 2017, 38: 1070–1078. doi: 10.3174/ajnr.A5086
- Ong M.S., Kohane I.S., Cai T., Gorman M.P., Mandl K.D.: Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol., 2014, 71: 569–74. doi: 10.1001/jaman-eurol.2014.188
- Scheffer, I.E., Berkovic S., Capovilla G., Connolly M.B., French J., Guilhoto L. et al.: ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, 58: 512–521. Doi: 10.1111/epi.13709
- Sculier C., Gaínza-Lein M., Sánchez Fernández I., Lodden-kemper T.: Long-term outcomes of status epilepticus: A critical assessment. Epilepsia, 2018, 59: 155–169. Doi: 10.1111/epi.14515
- Steriade C., Britton J., Dale R.C., Gadoth A., Irani S.R., Linnoila J. et al.: Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions. Epilepsia, 2020, 61: 1341–1351. Doi: 10.1111/epi.16571
- Toledano M., Britton J.W., McKeon A., Shin C., Lennon V.A., Quek A.M.L. et al.: Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology, 2014, 82: 1578–1586. doi: 10.1212/WNL.0000000000000383
- Verbeek M.M., Notting E.A., Faas B., Claessens-Linskens R., Jongen P.J.: Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis. Acta Neurol. Scand., 2010, 121: 309–314. doi: 10.1111/j.1600-0404.2009.01242.x
- Vincent A.: Developments in autoimmune channelopathies. Autoimmun Rev., 2013, 12: 678–681. doi: 10.1016/j.autrev.2012.10.016
- Vogrig A., Joubert B., André-Obadia N., Gigli G.L., Rheims S., Honnorat J.: Seizure specificities in patients with antibody-mediated autoimmune encephalitis. Epilepsia, 2019, 60: 1508– 1525. Doi: 10.1111/epi.16282
- Walker L., Sills G.J.: Inflammation and Epilepsy: The Foundations for a New Therapeutic Approach in Epilepsy? Epilepsy Curr., 2012, 12: 8–12. doi: 10.5698/1535-7511-12.1.8
- Yeshokumar A.K., Coughlin A., Fastman, J., Psaila K., Harmon M., Randell T. et al.: Seizures in autoimmune encephalitis – A systematic review and quantitative synthesis. Epilepsia, 2021, 62: 397–407. doi: 10.1111/epi.16807